text:
At a Glance
Why Get Tested?
To monitor the response to treatment of invasive breast cancer and to help watch for recurrence of the disease
When to Get Tested?
When you have been or are being treated for invasive breast cancer
Sample Required?
A blood sample drawn from a vein in your arm
Test Preparation Needed?
The Test Sample
What is being tested?
Cancer antigen 15-3 (CA 15-3) is a protein that is produced by normal breast cells. In many people with cancerous breast tumors, there is an increased production of CA 15-3 and the related cancer antigen 27.29. CA 15-3 does not cause cancer; rather, it is shed by the tumor cells and enters the bloodstream, making it useful as a tumor marker to follow the course of the cancer.
CA 15-3 is elevated in only about 10% of women with early localized breast cancer but is elevated in about 80% of those with metastatic breast cancer.
CA 15-3 may also be elevated in healthy people and in individuals with other cancers (e.g., colon, lung, pancreas, ovary, or prostate malignancies) or certain conditions (e.g., cirrhosis, hepatitis, and benign breast disease).
How is the sample collected for testing?
A blood sample is obtained by inserting a needle into a vein in the arm.
NOTE: If undergoing medical tests makes you or someone you care for anxious, embarrassed, or even difficult to manage, you might consider reading one or more of the following articles: Coping with Test Pain, Discomfort, and Anxiety, Tips on Blood Testing, Tips to Help Children through Their Medical Tests, and Tips to Help the Elderly through Their Medical Tests.
Another article, Follow That Sample, provides a glimpse at the collection and processing of a blood sample and throat culture.
Is any test preparation needed to ensure the quality of the sample?
No test preparation is needed.
The Test
Common Questions
Ask a Laboratory Scientist
This form enables you to ask specific questions about your tests. Your questions will be answered by a laboratory scientist as part of a voluntary service provided by one of our partners, American Society for Clinical Laboratory Science. If your questions are not related to your lab tests, please submit them via our Contact Us form. Thank you.
* indicates a required field
Article Sources
NOTE: This article is based on research that utilizes the sources cited here as well as the collective experience of the Lab Tests Online Editorial Review Board. This article is periodically reviewed by the Editorial Board and may be updated as a result of the review. Any new sources cited will be added to the list and distinguished from the original sources used.
Sources Used in Current Review
(Revised 2012 October 18). Tumor Markers. American Cancer Society [On-line information]. PDF available for download at http://www.cancer.org/acs/groups/cid/documents/webcontent/003189-pdf.pdf through http://www.cancer.org. Accessed October 2012.
Thaker, N. et. al. (Updated 2012 May 24). CA 15-3. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/2087491-overview#showall through http://emedicine.medscape.com. Accessed October 2012.
(© 1995-2012). Cancer Antigen 15-3 (CA 15-3), Serum. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/81607 through http://www.mayomedicallaboratories.com. Accessed October 2012.
Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 206-207.
Clarke, W., Editor (© 2011). Contemporary Practice in Clinical Chemistry 2nd Edition: AACC Press, Washington, DC. Pp 496, 500.
Pagana and Pagana. Mosby's Manual of Diagnostic and Laboratory Tests. Fourth Edition. Pg 142.
Sources Used in Previous Reviews
Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].
Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.
Check, W. (1998 July) Reaching agreement on tumor markers. CAP Today, In the News [On-line journal]. Available online at http://www.cap.org/captoday/archive/1998/julycover.html through http://www.cap.org.
NCI (1998 April 27). Tumor markers. National Cancer Institute, Cancer Facts [On-line information]. Available online at http://cis.nci.nih.gov/fact/5_18.htm through http://cis.nci.nih.gov.
ACS (2000 July 19). Tumor Markers. American Cancer Society, Prevention and Early Detection [On-line information]. Available online through http://www.cancer.org.
AACC (2001 July 27) Use of Tumor Markers in Cancer Patients Leads to Better Detection, Decreasing Mortality. AACC Media Center, American Association for Clinical Chemistry [On-line press release]. PDF available for download at http://www.aacc.org/media/TumorMarkers.pdf through http://www.aacc.org.
ASCO (1996 May 17, adopted, revision every 3 years). CA 15-3 as a Marker for Breast Cancer. American Society for Clinical Oncologists, Clinical Practice Guidelines for the Use of Tumor Markers in Breast and Colorectal Cancer [On-line guidelines]. Available online at http://www.asco.org/prof/pp/html/guide/tumor/m_tumor10.htm through http://www.asco.org.
Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 214-215.
Clarke, W. and Dufour, D. R., Editors (© 2006). Contemporary Practice in Clinical Chemistry: AACC Press, Washington, DC. Pp 247.
Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 206-207.
(Revised 2008 December 08). Tumor Markers. American Cancer Society [On-line information]. Available online at http://www.cancer.org/docroot/PED/content/PED_2_3X_Tumor_Markers.asp?sitearea=PED through http://www.cancer.org. Accessed August 2009.
(Updated 2009 May) Tumor Markers. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/resources/print/TumorMarkers.pdf through http://www.arupconsult.com. Accessed August 2009.
Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER and Bruns DE, eds. 4th ed. St. Louis, Missouri: Elsevier Saunders; 2006, Pp 770-771.
Park, B et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Annals of Oncology 2008 19(4):675-681. Available online at http://annonc.oxfordjournals.org/cgi/content/full/19/4/675 through http://annonc.oxfordjournals.org. Accessed September 2009.
Merck (2000). Cancer and the Immune System. The Merck Manual of Medical Information Home Edition, Section 15 Cancer, Ch 163 [On-line information]. Available online at http://www.merck.com/pubs/mmanual_home/sec15/163.htm through http://www.merck.com.
Duffy, M. (1999). CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem [On-line journal]. Vol 36: 579-586. PDF available for download at http://www.leeds.ac.uk/acb/annals/annals_pdf/Sept%2099/ACB579.PDF through http://www.leeds.ac.uk.
Srirangam, S. and Harland, R. (2001). Management of Advanced Breast Cancer. Forum for Registrars In Surgical Training [On-line information]. PDF available for download at http://www.frist.org/asit/meetings/yearbook2001/BREAST%20CANCER.pdf through http://www.frist.org.


text:
Dan Steven Veljovich, M.D.Dan Steven Veljovich, M.D.
Gynecologic Oncology, Gynecology, Robotic Surgery
Abdominal Surgery, Abnormal Pap Smears, Bilateral Salpingo-Oophorectomy (Laparoscopic), Bilateral Salpingo-Oophorectomy (Robotic), Blood Management Techniques, Bloodless Surgery, Cancer Institute, Cancer Screening, Cancer Surgery, Cervical Cancer, Cervix Dysplasia, da Vinci (Robot-Assisted Surgery), Dilatation & Curettage (D & C), Dysplasia, Endometrial Bx & Aspiration, Endometrial Cancer, Endometriosis, Female Urology, Genital Warts, GYN Reconstructive Surgery, Gynecologic Cancer Surgery (Robotic), Gynecologic Pathology, Gynecological Surgery, Gynecological Surgery (Robotic), Hysterectomy, Hysterectomy (Laparascopic Supracervical), Hysterectomy (Robotic), Hysterectomy Total (Laparascopic), Hysterectomy Vaginal (Laparoscopic-assisted), Incontinence (Female), Laparoscopic Surgery, Laparoscopy, Loop Electrical Excisional Procedure, Minimally Invasive Procedures, Minimally Invasive Surgery, Office Surgery & Procedures, Oncologic Surgery, Oncology, Ovarian Cancer, Ovarian Cyst Removal, Pelvic Floor Problems, Pelvic Organ Prolapse, Pelvic Prolapse, Pelvic Support Problems, Pelvic Surgery, Prolapse, Sacrocolpopexy (Robotic), Stress Incontinence (Females), Urinary Incontinence, Vaginal Hysterectomy, Vaginal Surgery, Women's Health
- Accepting Children: Yes
- Accepting New Patients: Yes
- Accepting Medicare: Yes
- Accepting Medicaid/DSHS: Yes
Bill Insurance, VISA, Master Card, Cash, CheckInsurance Accepted:
Call officeAdditional Information:
Seattle Magazine's "Top Doctors for Women", 2003
Dr. Veljovich was voted "Top Doctors" in Seattle Magazine (2013, 2014).
Surveys were mailed to physicians in King, Pierce, Snohomish and Kitsap counties. The survey asked physicians to name the provider they would seek out or recommend to loved ones.
My goal as a surgeon and oncologist is to maximize the chances of cure and remission while attempting to preserve the patient's quality of life and dignity as much as possible through the process by utilizing proven, effective therapies and emphasizing a minimally invasive robotic approach to surgery whenever feasible and possible. To provide a level of care I would want for my own family members entails a strong commitment to my profession, compassion towards my patients, and a passion for lifelong learning which allows me to stay ahead of the curve on medical and surgical therapies of cancer and complex gynecological problems.Personal Interests
Snowboarding, running, travelling with my family, seeing our National Parks, coaching soccer and being with my 3 kids and wife.Medical School
University of VirginiaResidency
University of VirginiaFellowship(s)
University of North CarolinaBoard Certifications
Diplomate, American Board of Obstetrics and GynecologyLanguages:
English, Some Medical SpanishProfessional Associations:
Society of Gynecologic Oncologists, American College of Obstetrician/Gynecologists, Seattle Gynecological Society, Pacific Coast OB/GYN Society, American Medical AssociationAwards:
President, Seattle Gynecological Society, Top Doc for Women Seattle Magazine, Golden Stethescope Award Seattle Metropolitan MagazineAdditional Information:
Seattle Magazine's "Top Doctors for Women", 2003
Dr. Veljovich was voted "Top Doctors" in Seattle Magazine (2013, 2014).
Surveys were mailed to physicians in King, Pierce, Snohomish and Kitsap counties. The survey asked physicians to name the provider they would seek out or recommend to loved ones.
Sentinel Lymph Node Dissection in Endometrial Cancer (ongoing trial at Swedish)
Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 2011 Aug 117(16):3731-40.
Surgical Outcomes in gynecologic oncology in the era of robotics: analysis of first 1000 cases. Am J Obstet Gynecol 2011 Jun 204(6):551.
Treatment of recurrent of platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of Puget Sound Oncology Consortium. Gynecol Oncol 2008 Aug 110(2): 146-51.
Robotic surgery in gynecologic oncology: program initiation and outcomes after the first year with comparison with laparotomy for endometrial cancer staging. Am J Obstet Gynecol 2008 Jun 198(6): 679.
Suite 1500
Seattle, WA 98104
Phone: (206) 965-1700
Fax: (206) 965-1736
- Thursday
- 9:00 AM to 4:00 PM
Map & Directions
751 NE Blakely Drive
Issaquah, WA 98029
Phone: 2069651700
Map & Directions
1120 112th Ave NE
Bellevue, WA 98004
Phone: 2069651700
Map & Directions
12303 NE 130th Lane #400
Kirkland, WA 98034
Phone: 2069651700
Map & Directions
Physicians: Is this your profile? Click here for info
Watch VideoPlay
This provider is affiliated with:
Physicians: Is this your profile? Click here for info

subset: commoncrawl


text:
Mammut Women's Ultimate Hoody
The Mammut Women's Ultimate Hoody is a hooded softshell jacket for alpine climbing and backpacking. The Ultimate Hoody is made with Gore Windstopper three layer softshell, allowing for plenty of movement and breathability, all while blocking the harshest of winds. The hood fits close and cinches tight with drawstrings that are on the inside, preventing the wind from entering. The thumb loops keep hands warm, and close up when not in use to protect your forearms. When your hike rises your body temperature, a long side zip is available for quick ventilation. The two side pockets secure your glove liners close at hand, accessible even when wearing your pack. Onward into the wind, undeterred.
FEATURES of the Mammut Women's Ultimate Hoody
- The evolution of a classic
- Windstopper material with 2-color backing, elastic and robust, can be used throughout the year, exclusively developed with Gore
- Well-made hood with clean closing, reinforced shield and 2-point regulation, which does not give the wind any Contact surface due to the fact that the drawstrings are inside
- Closed thumb loop: Functional, thumb loop remains completely closed when not in use and therefore does not allow cold to penetrate
- 2 side pockets with zip and reinforced with tape
- Easily accessible even when carrying a backpack
- Multi-media pocket outlet with loop on the inside
- Very clean finish with flat seams to improve functionality
- Bonded front flap as wind and chin protection with Ultimate embossing
- Very long side zip for optimum ventilation
- Well-fitting waistband with elastic inside edge
- With membrane
- Areas of Use: Mountain Hiking, Backpacking, Classical Alpinism
SPECIFICATIONS of the Mammut Women's Ultimate Hoody
- Weight: 490 g
- Main Fabric: Gore Windstopper Soft Shell 3-Layer 10620
- Face Material: 100% Polyester
- Membrane: 100% Polytetrafluorethylene
- Backing: 100% Polyester
custy reviews
for the Mammut Women's Ultimate Hoody
Average Custy Rating:
(based on 4 reviews)
|Love it
|Big Ups
Over 45
Viewing All
My first Mammut jacket has just arrived. Well done, Moosejaw, your service was excellent (this is the first time I have ordered on line from Moosejaw). I am tickled with the jacket. I must admit to owning many different brands of jackets (Arc'teryx, Patagonia, Icebreaker, etc.) and I think this Mammut is going to be a favourite. From reading reviews I decided to go up a size to a medium and I am really glad I did. I usually take a size small or xs (height 5'3" and weight 117 lbs, and long arms).
I pulled it out of the package and loved the Kiwi color (the photo is pretty true to color), but was so disappointed when I put it on because the sleeves were way too short. The thumb-loop pulled and kind of dug into my hand... it was really uncomfortable. Even when I wore the jacket at my wrists, it was too short. I walked outside, and the jacket was great: stopped the wind, lightweight, hood was great, color cute, fit well everywhere else except the arms. I debated about just going a size up for the sleeves, but since the jacket fit well everywhere else, just decided to return it. I'm about 5'7, 150 and ordered a M.
I tried on several jackets until I found this one - it is the perfect coat for anything. I wore it to a Tigers game and then threw it on the next day to add a cute white spark to my outfit (I bought the white one). Several compliments later....I love it even more!!Also, I am excited to wear it in a 10K I am doing in Thanksgiving- I think the weight and color will be the perfect combination.I will not forget this brand - its comfy, cool and versatile!


text: Loads of eager high school seniors crowded into the Conant Performing Arts Center on the Oglethorpe University campus in January 2010 for our annual Scholarship Weekend. The event is an important and unique opportunity for prospective students—including theater majors—to compete for one of many full-ride scholarships. I can personally attest to the anxiety, exhilaration, and enthusiasm that is included in this event, as I competed not too long ago, but now that I am on the other side, I have a slightly different perspective. Continue reading


text:
GRAND JUNCTION, Colo (KKCO)-- Full recap of local high school football on the Friday Night Football Blitz.
Below are the scores from week 4:
Green Mountain Def. Grand Junction Central 21-14
(9) Grand Junction Def. Mountain Range 28-14
Highlands Ranch Def. Fruita Monument15-7
(7)Grand Valley Def. Gunnison 40-20
(2) Palisade Def. Battle Mountain 45-0
(1)Rifle Def. Cortez 60-6
(18) Montrose Def. Hinkley 60-0
Delta Def. Moffat County 21-14
Paonia vs. Dolores was postponed until 1 pm on Saturday.
KKCO firmly believes in freedom of speech for all and we are happy to provide this forum for the community to share opinions and facts. We ask that commenters keep it clean, keep it truthful, stay on topic and be responsible. Comments left here do not necessarily represent the viewpoint of KKCO 11News.powered by Disqus


text:
The best known American half-tracks were the M series made as a standardized design by Autocar, Diamond T, International and White. The M series had a similar front end to the White M3A1 Scout Car but used more powerful engines: a 147bhp 6.3-liter White AX in the Autocar, Diamond T, and White, and a 143bhp 1HC in the International. Each version had four-speed gearboxes with two-speed transfer boxes and drive to the front axle as well as the tracked bogie. The M series half-tracks were widely used by US forces in most theatres of the war, and were also supplied under the Lend-Lease Program to Great Britain, Canada and the Soviet Union. A total of 41,170 were made.
First deployed during the end of WWII and then again in the Korean War, the Maxom quadruple .50 caliber AA machine gun mount was called "Meat Chopper" because of its impressive firepower when used against human wave attacks.
Pictured here is a 1:32 scale diecast replica of a US M16 Multiple Gun Motor Carriage that was attached to the 3rd Armored Division then serving in Normandy during 1944. Comes with two figures: a gunner and a spotter.
Sold Out!
Length: 8 inches
Width: 2.8 inches
Height: 3.25 inches
Release Date: June 2012
Historical Account: "Hedgerows" - The Battle of Normandy was fought in 1944 between Nazi Germany in Western Europe and the invading Allied forces as part of the larger conflict of World War II. Over sixty years later, the Normandy invasion, codenamed Operation Overlord, still remains the largest seaborne invasion in history, involving almost three million troops crossing the English Channel from England to Normandy in then German-occupied France. It is most commonly known by the name D-Day.
The primary Allied formations that saw combat in Normandy came from the United States of America, United Kingdom and Canada. Substantial Free French and Polish forces also participated in the battle after the assault phase, and there were also contingents from Belgium, Czechoslovakia, Greece, the Netherlands, and Norway.
The Normandy invasion began with overnight parachute and glider landings, massive air attacks, naval bombardments, and an early morning amphibious phase began on June 6th. The 'D-Day' forces deployed from bases along the south coast of England, the most important of these being Portsmouth. The battle for Normandy continued for more than two months, with campaigns to establish, expand, and eventually break out of the Allied beachheads, and concluded with the liberation of Paris and the fall of the Falaise pocket in late August 1944.
The Battle of Normandy was described thus by Adolf Hitler: "In the East, the vastness of space will... permit a loss of territory... without suffering a mortal blow to Germany's chance for survival. Not so in the West! If the enemy here succeeds. consequences of staggering proportions will follow within a short time."


text:
United States >
All 3M Products >
Electronics >
Communication Technologies
Products by Category
What's New
3M™ Crimplok™+ Jacketed Connectors
These new connectors provide fast field installation of 1.6 to 3.0 mm jacketed singlemode fiber.
Learn More »
3M™ Slim Lock Family
The 3M™ Slim Lock Closure Family now includes weatherproofing options for DIN-716 and mini-DIN and connectors.
The New 3M™ Easy Cleaver
Discover the latest cutting edge innovation from 3M.
3M Passive Optical LAN Solutions
Passive Optical LAN Solutions can deliver gigabit speeds over 12 miles with 5 nines reliability.
Communication Products Catalog
Click here for the latest Communication Products Catalog, which includes information on all our available products.
3M Residential Solutions
3M offers a range of fiber based Residential Solutions--from outside the residence to inside the living unit.
Solutions by Network
Backhaul solutions with the flexibility of fiber and copper.
More info >
Enable fast and easy installs with considerable savings.
High-speed copper solutions and fiber optic products for FTTP.
Fiber optic speeds without the high cost required by FTTH.
Consumes less energy for lower deployment and operating expenses.
Residential network solutions for high performance and low TCO.
Designed to increase efficiency and reduce energy.
Structured cabling solutions for both copper and fiber networks
News & Updates
Follow us for the most up to date information
Scan this code to access the mobile version of this site or go to m.3m.com/telecom on your mobile device.
© 3M 2015. All Rights Reserved.


text:
1saleaday has Turtle Beach Ear Force X41 Wireless Headset for Xbox 360 (Refurbished) for $54.99. Shipping is free. Thanks DJ3xclusive
Frontpage Deal
Turtle Beach Ear Force X41 Wireless Headset for Xbox 360 (Refurbished) $55 + Free Shipping (expired)
Original Post
DJ3xclusive ( ) Feb. 12, 2013 at 8:59pm
Product Link <<< click there
Pretty much the cheapest you can get for very good wireless gaming headset for xbox 360
Dolby 7.1 Channel Surround Sound
Product Link <<< click there
Pretty much the cheapest you can get for very good wireless gaming headset for xbox 360
Dolby 7.1 Channel Surround Sound
- The Ear Force X41 transmitter uses a 150MPS Digital Signal Processor (DSP) to deliver genuine Dolby Digital sound, Dolby Pro Logic IIx, and Dolby Headphone surround sound processing technologies - the industry-standard formats for encoding multi-channel sound in XBOX 360 games and DVD movies. The X41 uses the latest version of Dolby technology to create realistic game sound in 7.1 channels for improved surround sound accuracy.
- The X41 transmitter incorporates the latest Dolby Pro Logic IIx decoding system for surround sound realism from Dolby Pro Logic II encoded audio. When used with stereo sources, the Dolby Pro Logic Decoder also enhances the sound by spreading the stereo signal to provide a "wider" effect. This results in a richer, fuller sound than normal stereo - almost as if it originates from outside of the headphones.
- The Ear Force X41 transmits game audio to the headset with an uncompressed wireless digital radio frequency (RF) signal to deliver CD-quality sound that rivals professional-grade wired headphones. Best of all, the wireless RF signal does not require "line of sight" to operate. That means you can stand anywhere near your XBOX 360 and hear a clear, noise-free signal.
- If you've ever had trouble hearing teammates on XBOX LIVE when the game action heats up, then you know how frustrating it can be when you have to keep adjusting the chat volume. Chat Boost fixes this problem by automatically adjusting the XBOX Live chat level when the game gets louder, so chat from teammates isn't lost in the exciting parts of your game. As the game sound gets louder, Chat Boost turns up the chat volume automatically so you can still hear what everyone is saying.
- It's a simple solution to an annoying problem, and it all happens automatically - so you don't have to adjust anything!
- It's hard to hear yourself speak when a headset is covering your ears. The X41 corrects this annoyance with its microphone monitoring feature. The X41 adds a portion of the microphone signal into the headset signal, so you can hear a portion of your voice along with incoming chat and game audio. Microphone monitoring not only prevents you from talking too loud or accidentally yelling into the mic, it also eliminates that annoying "clogged ears" feeling when talking while the headset is covering your ears.
- The X41 headset DSP also lets you turn on a Bass Boost feature that produces deep, rich bass tones by increasing the volume of low frequency sounds - just like turning up the volume on the sub-woofer on your home theater system. Bass Boost improves your gaming experience by kicking-up the sound level of explosions, gun shots and other deep-bass sound effects, making them even more dramatic.
- The X41 transmitter includes a headphone output jack with volume control to connect an optional pair of wired headphones in addition to the wireless X41 headset. This jack outputs the same high-quality Dolby Headphone 7.1 surround sound that's being transmitted to the wireless X41 headset, which allows two people to hear the game sound at the same time.
- Separate volume controls let you adjust the game and chat levels individually, so you can easily balance them and never have to worry about missing a cue from your teammates.
- The X41 has a "battery booster" circuit that squeezes every last bit of power from the batteries and assures high quality sound until they're completely dead. This allows a pair of AAA Alkaline batteries to last for as long as 25 straight hours of game play. You can also buy standard rechargeable batteries in place of Alkaline batteries.
- The transmitter is powered by a single USB port on your XBOX, or from a nearby PC or laptop. So there is no need to fuss with a separate AC power adapter.
Wiki Community Board
This can and should be used by you to post updated deal information.
Be sure to read this because it may contain answers to your questions!
This can and should be used by you to post updated deal information.
Be sure to read this because it may contain answers to your questions!
If you are thinking about getting a set of these for PC-use see post #17
video link on how to connect x41 to pc and ps
video link on how to connect x41 to pc and ps
View Forum Thread
116 Comments
Yes This has been the lowest price seen so far. It always hovered around $60 to $80 refurbished across the web
DJ3xclusive ( ) Feb. 12, 2013 at 9:24pm
Yes This has been the lowest price seen so far. It always hovered around $60 to $80 refurbished across the web
Josecuervo100 ( ) Feb. 12, 2013 at 9:30pm
Amazing deal. But for some reason I don't see it when I sign in.
Devedander ( ) Feb. 12, 2013 at 9:34pm
Yeah link to product? I want in...
It's working for me. Clear your cookies and trying clicking the link again
Click Me
DJ3xclusive ( ) Feb. 12, 2013 at 9:40pm
Click Me
I think it works with anything with optical audio out. But for the chat feature to work you would have to buy an additional adapter.
Sweet product link worked, in 4 1!
Devedander ( ) Feb. 12, 2013 at 9:43pm
Click Me
ghostofdavid ( ) Feb. 12, 2013 at 9:48pm
I just took back my 199 Tangos because I realized I wasn't an idiot who wanted to pay that much for terrible sounding headphones.
I might get these. Because I'm still an idiot. Not sure how to hook these up with surround sound... I'll google it later.
I might get these. Because I'm still an idiot. Not sure how to hook these up with surround sound... I'll google it later.
Dentalll18 () Feb. 12, 2013 at 10:43pm
This seems like a very good price for a wireless headphone, but does it has good surround sound for movies and music? Most the reviews I looked up seem to aim toward gaming.
I suspect they work fine... appears they connect to anything with optical or RCA connectors...
Devedander ( ) Feb. 12, 2013 at 10:51pm
- Add To Existing List
- Favorites


text:
Search by campus:
Contact Us:
Department of Anthropology
Kent State University
226 Lowry Hall
Mark Seeman, Professor Emeritus, was on the Kent State Design and Fabricating Team for the new May 4 Visitors Center located in Taylor Hall. The Center was dedicated on May 4, 2013, and is now open to the public!
As a top Ohio undergraduate and graduate school, Kent State's eight campuses offer the resources of a large university with the friendly atmosphere of a liberal arts college. Enroll today to start pursuing your future at one of the best colleges in Ohio. We've been educating graduates for over 100 years; join us today.
Copyright 2014
Kent State University Kent, Ohio 44242 Phone: 330-672-3000


text:
25 October - European Day of Civil Justice
On 5 June 2003, the Ministers' Deputies of the Council of Europe decided to launch a European Day of Civil Justice, jointly with the European Commission.
Celebrated yearly on 25 October by member states organising a series of events in this framework, this manifestation aims to bring justice closer to citizens, to inform them on their rights through simulation of procedures and information sessions open to students, professionals of justice and general public and also through open doors to their courts.
The Council of Europe and the European Commission invite their member states to inform them of all events organised in this context. European citizens can find out about events once the Secretariat has been notified of them.
2012 Edition
The Secretariat of the CEPEJ and the representatives from the European Commission will participate in the main event, which will take place in Vilnius (Lithuania) on 25 October 2012, in presence of the Minister of Justice of Lithuania, Mr Remigijus Šimašius.
On this occasion, the 2012 "Crystal Scales of Justice" Prize will be awarded by the Council of Europe and the European Commission.


text:
Jump to navigation
Title 45 published on 2014-10-01
no entries appear in the Federal Register after this date.
This is a list of United States Code sections, Statutes at Large, Public Laws, and Presidential Documents, which provide rulemaking authority for this CFR Part.
This list is taken from the Parallel Table of Authorities and Rules provided by GPO [Government Printing Office].
It is not guaranteed to be accurate or up-to-date, though we do refresh the database weekly. More limitations on accuracy are described at the GPO site.
§ 1352 - Limitation on use of appropriated funds to influence certain Federal contracting and financial transactions
§ 4951 - Congressional statement of purpose
§ 4952 - Authority to operate VISTA program
§ 4953 - Selection and assignment of volunteers
§ 4954 - Terms and periods of service
§ 4955 - Support services
§ 4956 - Participation of program beneficiaries
§ 4957 - Participation of younger and older persons
§ 4958 - Limitation on funds appropriated for grants and contracts for direct cost of supporting volunteers in programs or projects
§ 4959 - Repealed.
§ 4960 - Applications for assistance
§ 5060 - Repealed.


text:
Cleansing and Detox Diets Center - Dale City, VA
WebMD Physician Directory
Dale City, Virginia
Cleansing and Detox Diets
Cleansing and detox diets introduction
If you're looking for a way to lose weight quickly and feel better (and who isn't?), you might be tempted to try a fad "detox" diet or a "cleanse" method." These die...
Other Related Cleansing and Detox Diets Articles
Emergency Contact for Dale City
Nearby Dale City Hospitals *
Sentara Potomac Hospital
Dewitt Army Community Hospital
Prince William Hospital
Inova Mount Vernon Hospital
Inova Fairfax Hospital
Northern Virginia Mental Health
Stafford Hospital
Inova Fair Oaks Hospital
Inova Alexandria Hospital
Dominion Hospital
Fort Washington Medical Center
Virginia Hospital Center
Halquist Memorial Inpatient Ctr
Civista Medical Center
Speciality Hosp Of WA-Hadley
Reston Hospital Center
United Medical Center
Saint Elizabeths Hospital
Georgetown University Hospital
George Washington Univ Hosp
Sibley Memorial Hospital
Psychiatric Institute
Mary Washington Hospital
Specialty Hospital Washington
Snowden At Fredericksburg
Howard University Hospital
Southern Maryland Hospital Ctr
Children's National Medical Ctr
Medstar National Rehab Hospital
Washington Hospital Center
Fauquier Hospital
Washington DC VA Medical Center
Malcolm Grow Med Ctr 79Th
King Health Center
Seton House Providence Hospital
Suburban Hospital
NIH Clinical Center
Providence Hospital
Walter Reed Ntnl Mltry Med Ctr
The HSC Pediatric Center
Prince George's Hospital Center
Washington Adventist Hospital
Holy Cross Hospital
Spotsylvania Regional Med Ctr
Inova Loudoun Hospital
Saint Luke Institute
Adventist Rehab Of Maryland
Shady Grove Adventist Hospital
Adventist Behavioral Health
Doctors Community Hospital
Grafton Intergrated Health Net
*Provider Directory Terms of Use:
The WebMD 'Provider Directory' is provided by WebMD for use by the general public as a quick reference of information about Providers. The Provider Directory is not intended as a tool for verifying the credentials, qualifications, or abilities of any Provider contained therein. Inclusion in the Provider Directory does not imply recommendation or endorsement nor does omission in the Provider Directory imply WebMD disapproval.


text:
16-03-2012 16:31 - last edited on 16-03-2012 16:35 by Iris9290
I am so disappointed in Nokia . How can the Nokia N9 not support whatsapp. I wish i never bought this phone. Nokia use to be the best celluar phones for me but not anymore. So you know what people out there, sell these phones they of no use. Nokia doesn't consider what the customer wants. When you buy the cellphones in the shops they don't even have cellpones that you can play around with, they have these dummies that you can only look at. Now i can't even return this phone, and i only have it for 15 days. nokia needs to be made aware of this that all Nokia N9 owners are upset about not being able to download it whatsapp!!!!!!!!!!!!!!!!!!!!!!
Moderators note: comment about OS Android removed, the N9 runs on MeeGo
16-03-2012 17:12
looks like you didn't read my previous post properly....
WhatsAPP will be available soon.
Read this article:
16-03-2012 17:42
19-03-2012 14:02
19-03-2012 14:37 - edited 19-03-2012 14:38
Notwithstanding the fact that the Meego community is porting the app and it's coming soon, I think you're barking at the wrong tree. It's Whatsapp Inc. that you should be upset or disappointed about. They develop the app for all the platforms, and not the phone makers themselves. And for-god-knows-why, they decided to ditch Meego. Ask @Whatsapp on Twitter or something, maybe u'll get the answer.
Moreover, Nokia doesn't have the obligation to tell what cross-platform apps are available and not for its phones. If it starts doing so, then all of its time will be spent on answering questions on Instagram, Whatsapp and other apps alike.
21-03-2012 19:03
Any news? Whatsapp for N9....?
21-03-2012 20:49
Here you can follow the discussion and development:
29-03-2012 20:04 - last edited on 29-03-2012 21:08 by Sheldrick
I wish i had whatsapp but the simple fact that if whatsapp team doesn't give a damn about we over 10000 ppl that wants it then they don't deserve our respect and time to even try the app. ebuddy xms should be used as those guys been doing the app for all platforms,and cared about us the users.And here it is not about what meego has or not,it's a about being a cross platform app and you should keep your users happy cause it is not only meego users to keep in touch but other OS member that want to keep in touch with us,therfore that is totally disrespectfull to all users.
MODERATORS NOTE: The profanities have been removed. Offensive language is not allowed on the forums. Please do not use offensive language on the forums
19-04-2012 20:27
Progress was just updated with a youtube video of it in action. With it we can see development have come along nicely and just a matter of time before its released publicly. A little more patience is needed right now. Video can be found via link: N9 Fan Club
26-04-2012 9:30
An app named Whazapp will be released on May 1, 2012 . This is an unofficial release and developed by the Meego community, and is the same as Whatsapp. So all of us who have been waiting for Whatsapp have something to look forward to.
I think I read about it on Nokia Conversations/Meego forum/some other mobile tech sites.
17-05-2012 20:34
Beta of wazapp has been released:
More details here:
27-05-2012 8:27
20-06-2012 5:42
go to wazapp.im
13-08-2012 2:10
01-09-2012 3:34
I 2ed U we need whatapp,to be supported in N9 ,I will wait this month or I will start talking to all I know not to bay it .........So Please Please Don't let this stand longer , It's great device with whatsapp.
19-09-2012 4:42
19-09-2012 8:36
Search for "Wazapp" in http://talk.maemo.org/
03-12-2012 17:35
hey i've installed wazapp like whatsapp. friends of mine can c me on whatsapp's list but i cannot use it ((((((((((((
09-12-2012 5:49
You can download wazapp
29-03-2013 22:04


text:
BEST: Love the lattice! Kate Upton glammed up in a black and blue Louis Vuitton gown.
BEST: Karolina Kurkova was the golden girl, wearing an impeccably embellished Roberto Cavalli gown.
BEST: Berenice Bejo rocked a powerfully patterned Giambattista Valli Couture gown with an Olympia Le Tan clutch.
BEST: White hot! Diane Kruger looked Chanel chic in a short frock from the French brand's Resort 2013 collection, which featured purple embroidery.
BEST: Nutrisystem did her body good! Janet Jackson flaunted her slimmed-down figure and boobiful assets in a white Emilio Pucci peephole dress.
WORST: Kirsten Dunst experienced a frumpy fashion flop, wearing a two-tone Louis Vuitton gown that featured a colorfully embellished belt.
WACKY: Brit singer Jessie J took slitty to the extreme, wearing an animal print Louis Heal gown with black booties.
BEST: Supermodel Doutzen Kroes stunned in a white Versace column gown.
BEST: Milla Jovovich looked out of this world in an Atelier Versace sparkling gown, which she paired with Sergio Rossi heels.
WORST: Though Tara Reid looked more cleaned up than usual in her strapless gown, the awkward addition of her misplaced jewelry as well as her black clutch paired with nude heels ruined the overall look.
BEST: Petra Nemcova rocked a red hot strapless gown with silver heels.
BEST: Kim Kardashian showed off her assets in a yellow Elie Saab gown, and fortunately for her, no other stars got to the dress first!
WORST: Paris Hilton showed some skin in a white, sheer-paneled gown, but it didn't really suit her personality.
BEST: Kelly Rutherford looked just peachy in a gorgeously draped, one-shoulder gown.
WORST: Joely Richardson's ill-fitting hot pink frock drenched her figure in unflattering fashion.
WORST: Tamara Ecclestone may be from one the richest families in the world, but her look wasn't exactly elegant.
PHOTOS: The Best, Worst & Wackiest Dressed Stars At The amfAR Cinema Against Aids Gala


text:
Your location: Home
UK Department for International Development in Kenya (DFID Kenya)
DFID will deliver its programmes through wide-ranging partnerships with UN agencies, non-governmental and civil society organisations, private sector organisations and managing agents. There will be limited channelling of UK aid through Government of Kenya systems until there are measurable improvements in the government's management of public finances. DFID is also one of Kenya's largest development partners, supporting the Kenya Joint Assistance Strategy (2007-2012) which brings together 13 bilateral and four multilateral partners including the World Bank and UNDP. This arrangement has resulted in an increasingly effective division of labour, and a framework for mutual accountability with government.
Organizations, institutions and private sector companies at all levels and in a wide range of sectors can become engaged with the NWP by becoming a partner and making Action Pledges. Information about how organizations can become engaged with work on adaptation under the NWP can be found here.
© 2014 United Nations Framework Convention on Climate Change


text:
Author Affiliations: Department of General Internal Medicine, Zablocki Veterans Affairs Medical Center, and Department of Medicine, Medical College of Wisconsin, Milwaukee (Dr Jackson); Department of General Internal Medicine, Rakuwakai Otowa Hospital, Kyoto, Japan (Dr Kuriyama); and Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine and Public Health, Kyoto, Japan (Dr Hayashino).
Context Botulinum toxin A is US Food and Drug Administration approved for prophylactic treatment for chronic migraines.
Objective To assess botulinum toxin A for the prophylactic treatment of headaches in adults.
Data Sources A search of MEDLINE, EMBASE, bibliographies of published systematic reviews, and the Cochrane trial registries between 1966 and March 15, 2012. Inclusion and exclusion criteria of each study were reviewed. Headaches were categorized as episodic (<15 headaches per month) or chronic (≥15 headaches per month) migraine and episodic or chronic daily or tension headaches.
Study Selection Randomized controlled trials comparing botulinum toxin A with placebo or other interventions for headaches among adults.
Data Extraction Data were abstracted and quality assessed independently by 2 reviewers. Outcomes were pooled using a random-effects model.
Data Synthesis Pooled analyses suggested that botulinum toxin A was associated with fewer headaches per month among patients with chronic daily headaches (1115 patients, −2.06 headaches per month; 95% CI, −3.56 to −0.56; 3 studies) and among patients with chronic migraine headaches (n = 1508, −2.30 headaches per month; 95% CI, −3.66 to −0.94; 5 studies). There was no significant association between use of botulinum toxin A and reduction in the number of episodic migraine (n = 1838, 0.05 headaches per month; 95% CI, −0.26 to 0.36; 9 studies) or chronic tension-type headaches (n = 675, −1.43 headaches per month; 95% CI, −3.13 to 0.27; 7 studies). In single trials, botulinum toxin A was not associated with fewer migraine headaches per month vs valproate (standardized mean difference [SMD], −0.20; 95% CI, −0.91 to 0.31), topiramate (SMD, 0.20; 95% CI, −0.36 to 0.76), or amitriptyline (SMD, 0.29; 95% CI, −0.17 to 0.76). Botulinum toxin A was associated with fewer chronic tension-type headaches per month vs methylprednisolone injections (SMD, −2.5; 95% CI, −3.5 to −1.5). Compared with placebo, botulinum toxin A was associated with a greater frequency of blepharoptosis, skin tightness, paresthesias, neck stiffness, muscle weakness, and neck pain.
Conclusion Botulinum toxin A compared with placebo was associated with a small to modest benefit for chronic daily headaches and chronic migraines but was not associated with fewer episodic migraine or chronic tension-type headaches per month.
Migraine and tension-type headaches are common. Although up to 42% of adults experience tension-type headaches sometime in their life, most do not seek medical advice. Migraines are less common, with a worldwide prevalence between 8% and 18%,1- 3 but are associated with greater disability.4,5 Migraine headaches are responsible for $1 billion in medical costs and $16 billion in lost productivity per year6 in the United States alone.
Headache treatment is either abortive or prophylactic. Abortive treatment manages the acute headache and prophylactic treatment aims to reduce the frequency or severity of the attacks. Common prophylactic medications include anticonvulsants, β-blockers, calcium channel blockers, serotonin reuptake inhibitors, and tricyclic antidepressants.7 Botulinum toxin A injections were first proposed as headache treatment when it was observed that patients with chronic headaches receiving cosmetic botulinum injections experienced headache improvement, prompting several case series that suggested benefit.8- 10 In October 2010, the US Food and Drug Administration approved botulinum toxin A for prophylactic treatment of chronic migraine headaches at a dose of 155 units divided among 31 injection sites, repeated as needed every 12 weeks, based on 2 clinical trials conducted in Europe and the United States.11,12 However, the literature on botulinum effectiveness for headaches is mixed. We performed a systematic review to assess the association of botulinum toxin A with reducing headache frequency when used for prophylactic treatment of migraine, tension, or chronic daily headaches in adults.
We followed the PRISMA guideline13 and accordingly followed a protocol (available to readers upon request). We searched for randomized trials of botulinum toxin A for headaches in adults using MEDLINE and EMBASE, the bibliographies of published systematic reviews, the Cochrane libraries (Database of Clinical Trials; Pain, Palliative, and Supportive Care Trials Register; Central Register of Controlled Trials), and performed a review of the bibliographies of all articles retrieved (eTable 1). The last search date was March 15, 2012. The search was supplemented by searches performed by medical librarians at our institution. We did not attempt to contact authors for original data or search for unpublished literature.
We included randomized clinical trials that evaluated botulinum toxin A treatment and its association with the reduction in frequency or severity of headaches. Trials had to be at least 4 weeks in duration. Treatment could be combined with other prophylactic and analgesic medications. Quiz Ref IDWe excluded headaches associated with other disorders, such as cervical dystonia and secondary headaches, such as postlumbar puncture headaches. Because the definition of headaches has changed over time, we reviewed each study's inclusion and exclusion criteria and attempted to categorize trials as episodic (<15 headaches per month) or chronic (≥15 headaches per month) and as migraine or tension. Some trials investigated chronic daily headaches14 and included chronic headaches of either tension or migraine type.
At least 2 authors (J.L.J., A.K., Y.H.) independently abstracted data, including study characteristics (setting, country of origin, language, and inclusion and exclusion criteria), information about the intervention (design, treatment characteristics, including dose and duration), subject characteristics (age, sex, ethnicity, assessment of comorbid psychiatric disease), and headache outcomes (frequency, intensity/severity, duration, global improvement/relief, analgesics used, adverse events).
For our primary outcome analysis, we followed International Headache Society recommendations15,16 and preferentially abstracted and pooled headache frequency (number of headaches per month) using weighted mean differences in a random-effects model. For studies not reporting headache frequency, outcomes were abstracted preferentially in this order: headache severity or a headache index that included frequency and severity.
We required all outcomes to be patient reported. For continuous outcomes, we abstracted the number of participants and the mean and variance of reported outcomes. Missing variances were calculated by using the sample size and means from reported P values.17 For dichotomous outcomes, we required at least 50% clinical improvement. We abstracted this data into 2×2 tables. For both continuous and dichotomous outcomes, we abstracted the outcome at all time points reported. We assessed article quality independently and in duplicate using the Cochrane Risk of Bias assessment tool18 and the Jadad scale (original 0-8 scale),19 with good interrater agreement (Jadad scale: intraclass correlation coefficient, 0.89-0.97). Disagreements were resolved by consensus.
For studies with more than 1 treatment group, we followed the Cochrane recommendation and combined groups by pooling the data into a single group.20 Summary effects were calculated by using the DerSimonian and Laird random-effects model.21 We assessed heterogeneity visually using Galbraith plots22 and statistically with Q statistics and I2.23 Our primary analysis was headache frequency, pooling weighted mean differences. We secondarily examined all studies, including those using other measures than frequency by calculating an effect size (standardized mean differences [SMDs]), the absolute difference between groups divided by the standard deviation. By convention, effect sizes more than 0.8 are considered large, those between 0.5 and 0.8 moderate, those between 0.2 and 0.5 small, and those less than 0.2 insignificant.24 To test the robustness of the random-effects models, we also calculated a predictive interval using the methods of Higgins25 and performed a noninformative random-effects Bayesian analysis using Winbugs.26 The Higgins predictive interval asks what range of outcomes could be expected with 95% confidence from future trials based on the observed trial heterogeneity using a t distribution.
Quality assessment was performed by using a component approach in which each domain's potential effect on our results was evaluated. In addition, we tested the effect of study sponsorship and use of intention-to-treat analysis (for trials with losses to follow-up). We assessed for small study effects (publication bias) using the methods of Peters et al27 for dichotomous and Egger et al28 for continuous outcomes. We explored potential sources of heterogeneity using stratified analysis and meta-regression.29 The analysis of the association of placebo with headache outcomes was performed by using random-effects meta-regression, clustered by the specific study.
All analyses were performed by using STATA version 12.0 or Winbugs. In creating our forest plots, we followed standard convention, in which the size of the box for each study is proportional to the contribution (weight) of each study to the pooled summary. The Zablocki Veterans Affairs review board reviewed and approved this manuscript for publication.
Our search produced 315 articles. Application of inclusion and exclusion criteria (eFigure 1) resulted in 27 placebo-controlled randomized trials11,12,30- 54 and 4 randomized comparisons with other medications (amitriptyline,55 prednisone,56 topiramate,57 and valproate58).
Among placebo-controlled trials, there were 5313 study participants, of which 1938 had episodic migraines, 1544 had chronic migraines (Table 1), 616 had chronic tension-type headaches (Table 2), and 1115 had chronic daily headaches (Table 1). One study with 21 participants evaluated patients with either episodic or chronic tension-type headaches (Table 2). The average age of participants was 42.1 years, with predominantly women (76%) (eTable 2). Trials averaged 19 weeks in duration, ranging between 84 and 270 days (Table 1). Most trials allowed continued use of prophylactic headache medications (85%) if patients were taking a stable dose and all allowed analgesic use.
Different protocols were followed for the botulinum injections (eTable 2). Quiz Ref IDAmong the 27 placebo-controlled trials, 20 used a fixed injection plan, in which patients were injected at a fixed, specific site. Seven trials used a follow-the-pain approach, in which painful points were elicited and injected. One trial used a combination of fixed and follow-the-pain protocols. Twenty-one studies injected botulinum toxin A at a single time point, although 6 studies performed injections at 3 time points spaced 90 days apart. The number of injections varied, ranging between 4 and 58. One trial compared injections into single muscle groups against injections into several muscle groups (range, 4-11).
Among 27 placebo-controlled trials, 10 evaluated patients with episodic migraine headaches, 5 assessed chronic migraines, 8 evaluated patients with chronic tension-type headaches, 1 evaluated a population of 21 patients with either episodic (n = 16) or chronic (n = 5) tension-type headaches, and 3 trials studied chronic daily headaches (migraine or tension-type headaches occurring >14 days per month [Table 1]), the majority of which (74%) experienced chronic migraine headaches. All but 2 placebo-controlled trials reported outcomes in terms of frequency. The trials of episodic migraines averaged 6.2 (95% CI, 5.0-7.4) headaches per month, trials of chronic migraine averaged 19.5 (95% CI, 14.8-24.2) headaches per month, trials of chronic tension-type headaches averaged 25.2 (95% CI, 22.9-27.8) headaches per month, and trials of chronic daily headaches averaged 17.5 (95% CI, 13.5-21.3) headaches per month. The trial with a combination of episodic tension-type (n = 16) and chronic tension-type (n = 5) headaches averaged 13.9 (95% CI, 11.5-14.7) headaches per month (eTable 2).
Botulinum toxin A was associated with a reduction in headaches per month for both chronic daily headaches (−2.06 headaches per month; 95% CI, −3.56 to −0.56; Q = 2.79, df = 2, I2 = 28.2%; P = .25) and chronic migraine (−2.30 headaches per month; 95% CI, −3.66 to −0.94; Q = 5.9, df = 4, I2 = 32.2%; P = .21) (Figure 1). There was no association of botulinum toxin A with a reduction in the number of episodic migraine headaches per month (0.05 headaches per month; 95% CI, −0.26 to 0.36; Q = 11.43, df = 8, I2 = 30.0%; P = .18) or chronic tension-type headaches (−1.43 headaches per month; 95% CI, −3.13 to 0.27; Q = 15.59, df = 6, I2 = 61.5%; P = .02) (Figure 1). A single trial that included participants with both episodic and chronic tension-type headaches found no association of botulinum toxin A with a reduction in headaches (3.70 headaches per month; 95% CI, −2.85 to 10.26).
Size of data markers is proportional to study weight.
There were 2 studies (1 chronic tension-type headache and 1 episodic migraine) that reported outcomes as headache indices rather than headache frequency. Reanalysis of these trials using SMDs also found no association of botulinum toxin A with improvement in the headache indices compared with placebo for chronic tension-type headache (SMD, −0.22; 95% CI, −0.51 to 0.07; Q = 15.57, df = 6, I2 = 55.0%; P = .03) or episodic migraine (SMD, −0.13; 95% CI, −0.33 to 0.07; Q = 26.40, df = 9, I2 = 65.9%; P = .002).
Eight studies reported on the likelihood of achieving 50% improvement in headache. Botulinum toxin A was associated with a greater likelihood of experiencing 50% improvement in chronic migraine headaches (2 studies: relative risk [RR], 2.21; 95% CI, 1.30-3.78; Q = 0.03, I2 = 0.0%; P = .86) (Figure 2). Compared with placebo, there was no association of botulinum toxin A with improvement in chronic daily headaches (1 study: RR, 1.15; 95% CI, 0.91-1.45), episodic migraine headaches (2 studies: RR, 1.00; 95% CI, 0.85-1.18; Q = 0.27, I2 = 0.0%; P = .61), or chronic tension-type headaches (3 studies: RR, 1.00; 95% CI, 0.57-1.76; Q = 2.30, df = 2, I2 = 12.9%; P = .15).
There were 4 trials that compared botulinum toxin A with other treatment modalities. In single trials, botulinum toxin A was not associated with reduction in headache frequency compared with topiramate (1.4 headaches per month; 95% CI, −2.5 to 1.3) or amitriptyline (2.1 headaches per month; 95% CI, −1.2 to 5.4) for prophylaxis against chronic migraine headaches. Botulinum toxin A was not associated with a reduction in headache frequency vs valproate in a study of patients with chronic and episodic migraines (0.84 headaches per month; 95% CI, 1.40-3.10) or in a study of patients with episodic migraines (0.3 headaches per month; 95% CI, −1.1 to 0.50). Botulinum toxin A was associated with a greater reduction in average headache severity (0-10 visual analog scale) than methylprednisolone in a single trial among patients experiencing chronic tension-type headaches (−2.5 headaches per month; 95% CI, −3.5 to −1.5).
Our data had moderate heterogeneity. Study quality varied, with total Jadad scores ranging between 2 and 8 (eTable 3). There was no relationship between total Jadad score and outcomes or between Jadad scores of more than 3 vs 3 or less and study outcomes. Sixty-five percent of studies used intention-to-treat analysis, although only 42% had adequate sequence generation, 35% concealed allocation, and 61% had adequately described blinding. There was no relationship between the outcomes and intention-to-treat analysis (P = .74), concealed allocation (P = .40), adequacy of sequence generation (P = .17), industry sponsorship (P = .16), blinding (P = .37), or dropouts (P = .40). We explored a number of potential sources of heterogeneity (eTable 4) and found no association of participant age, proportion of women, sample size, study duration, dropout rates, botulinum toxin A dose, or injection strategy with study outcomes. We found no evidence of publication bias for either continuous (Egger method, P = .93) or dichotomous outcomes (Peters method, P = .29). Because the studies were few and the tests for statistical significance depend on assumptions of normality that may not be reasonable with small samples, we reanalyzed our data using the Higgins t distribution and a noninformative Bayesian model. None of these results were statistically significant (eTable 5).
Patients receiving botulinum toxin A were more likely to report any adverse event than those injected with placebo (25 studies: RR, 1.25; 95% CI, 1.14-1.36), although they were not more likely to withdraw from the study (23 studies: RR, 1.04; 95% CI, 0.85-1.27) (Table 3). Quiz Ref IDSome adverse effects were more common among patients receiving botulinum toxin A, including blepharoptosis (RR, 9.5; 95% CI, 4.7-18.9), muscle weakness (RR, 8.9; 95% CI, 2.5-30.9), neck pain (RR, 4.7; 95% CI, 3.2-6.9), neck stiffness (RR, 3.2; 95% CI, 1.9-5.6), parasthesia (RR, 3.3; 95% CI, 1.3-7.9), and skin tightness (RR, 3.6; 95% CI, 1.6-8.3).
There was evidence for a favorable improvement in headaches in the placebo-treated study groups. Over the range of study durations (8-39 weeks), patients receiving placebo reported substantial improvement in headaches over time (eFigure 2). The standardized headache effect size decreased from 3.4 (95% CI, 2.62-4.14) to 1.26 (95% CI, −0.13 to 2.65) by day 270, a significant association (β = −0.0075; 95% CI, −0.012 to −0.003; r2 = 20%).
Quiz Ref IDOur analyses suggest that botulinum toxin A may be associated with improvement in the frequency of chronic migraine and chronic daily headaches, but not with improvement in the frequency of episodic migraine, chronic tension-type headaches, or episodic tension-type headaches. However, the association of botulinum toxin A with clinical benefit was small. Botulinum toxin A was associated with a reduction in the number of headaches per month from 19.5 to 17.2 for chronic migraine and from 17.5 to 15.4 for chronic daily headaches. We also found a strong association of placebo with improvement in headaches over time.
Given that botulinum toxin A is not associated with improvement in chronic tension headache, it is likely that the association with reduction in chronic daily headaches is due to its association with improvement among the majority of participants in the trials with chronic migraines. This is consistent with a subgroup analysis from one of the trials of chronic daily headache that demonstrated an association of botulinum toxin A with greater improvement for chronic migraines than chronic tension headaches.59
There does not appear to be a difference in outcomes when botulinum toxin A is injected in a fixed schedule, when certain muscle groups are injected, or when botulinum toxin A is injected using a follow-the-pain method. We found no differences in outcomes between injecting once or performing 3 injections at 90-day intervals. There was no difference in the number of muscle groups injected or the total botulinum toxin A dose used and study outcomes.
Quiz Ref IDOur finding of minimal benefit is contrary to findings from case series and open-label studies that suggested substantial benefits.60- 79 These differences in results may be due to a strong association of placebo with improved outcomes and the natural history of headaches, in which improvement is observed over time. The favorable placebo association has been reported previously for botulinum80 and has been observed in other symptom-based conditions, such as irritable bowel syndrome,81 overactive bladder,82 low back pain,83 and Crohn disease.84 Our findings underscore the importance of including placebo groups in clinical trials of symptom syndromes.
There are a number of prophylactic drugs that are associated with improved outcomes for headaches, including β-blockers (atenolol, metoprolol, propranolol), anticonvulsants (gabapentin, topiramate, valproate), the calcium channel blocker flunarizine, and tricyclic antidepressants (amitriptyline and clomipramine). The reported range of efficacy for these drugs varies from modest (effect size, 0.5-0.8) for most drugs (atenolol, metoprolol, propranolol, clomipramine, topiramate, and flunarizine) to large (effect size, >0.8) for amitriptyline and valproate. The effect sizes in our review are smaller than reported values in other reviews, suggesting that botulinum toxin A may be associated with less benefit than other common prophylactic medications for migraine headaches. However, the paucity of direct comparisons makes definitive conclusions difficult.
Although single trials found no differences between botulinum toxin A and amitriptyline55 or topiramate57 for chronic migraine headaches and no differences between botulinum toxin A and valproate58 for chronic tension-type headaches, none of these trials were designed as equivalence trials and all were underpowered to show even modest differences (amitriptyline power = 0.61, topiramate power = 0.28, and valproate power = 0.27). The trials of topiramate and valproate had significant loss to follow-up (topiramate, 18%; valproate, 45%) and the maximum doses of the 3 comparison medications were low, using only 50% of standard migraine prophylactic treatment doses (amitriptyline, 50 mg; topiramate, 100 mg; and valproate, 500 mg). Porta56 reported that botulinum toxin A was associated with better outcomes than methylprednisolone for chronic tension-type headaches. Given that our analyses demonstrated no association of botulinum toxin A with improved outcomes for chronic tension-type headaches, that corticosteroids are not generally used as a prophylactic medication for headaches, and that there are no trials of corticosteroids for use in prophylactic treatment of headaches, it is unclear how useful this comparison is clinically.
Our systematic review has limitations. First, for nearly all the headache types, there were relatively few studies and many of the studies were quite small. Our results could be spurious, particularly given that the meta-analysis is based on assumptions of normality for tests of significance. Analysis of the data using nonnormal approaches, approximate predictive distribution of a future trial, based on the extent of heterogeneity as suggested by Higgins et al25 or Bayesian methods26 suggests that botulinum toxin A may not be associated with benefit for any headache types. More trials are needed.
A second limitation is that we had only aggregate data. Many of the outcomes had considerable heterogeneity and the lack of patient-level data precluded fully exploring potential sources of differences between the studies. This makes it difficult to explore why botulinum toxin A is not associated with benefit for chronic tension-type headaches, even though it is associated with improved outcomes for chronic daily headaches. Third, headache is a chronic problem and all the trials were relatively short. At least 1 systematic review85 found that prophylactic treatment becomes more effective over time. Fourth, none of the studies evaluated more than 3 injections, 90 days apart. It is unclear whether a higher dosing strategy over time may be associated with greater benefit. Fifth, there are few comparisons between botulinum toxin A and other prophylactic medications, and these are underpowered or have other limitations that may prevent the ability to demonstrate benefit of botulinum toxin A. Although the reported SMD of benefit that has been associated with other prophylactic agents appears to be larger than the SMD we found for botulinum toxin A, the best way to make this determination is with direct comparative trials. In addition, we only included events from these randomized controlled trials. Observational studies and Food and Drug Administration adverse event reports likely include additional harms, particularly rare ones that may be missed in short-term, relatively small studies. We may have underestimated adverse effects of botulinum toxin A.
In conclusion, botulinum toxin A is not associated with greater benefit than placebo in prophylactic treatment of episodic migraine or chronic tension-type headaches. Botulinum toxin A may be associated with benefit in prophylaxis of chronic daily headaches and chronic migraine headaches. This beneficial association appears limited to patients with chronic migraine headaches and the absolute reduction in the number of headaches is only 2 to 3 days a month.
Corresponding Author: Jeffrey L. Jackson, MD, MPH, Department of Medicine, Medical College of Wisconsin, 5000 W National Ave, Milwaukee, WI 53295 (email@example.com).
Author Contributions: Dr Jackson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Jackson, Kuriyama, Hayashino.
Acquisition of data: Jackson, Kuriyama, Hayashino.
Analysis and interpretation of data: Jackson.
Drafting of the manuscript: Jackson.
Critical revision of the manuscript for important intellectual content: Jackson, Kuriyama, Hayashino.
Statistical analysis: Jackson.
Study supervision: Hayashino.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Neither Dr Jackson nor Dr Kuriyama has any conflicts to disclose. Although Dr Hayashino has accepted speaker fees from a number of pharmaceutical firms, none of these manufacture botulinum toxin A.
Disclaimer: All opinions in this article are those of the authors and should not be construed to reflect in any way those of the US Department of Veterans Affairs.
Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012;307(16):1736-1745.
eTable 1. Search Strategy
eTable 2. Study Characteristics
eTable 3. Quality Assessment
eTable 4. Sensitivity Analyses
eTable 5. Data Analysis With t-Distribution and Non-informative Bayesian Analysis
eFigure 1. Study Flow
eFigure 2. Response to Placebo Over Time
This supplementary material has been provided by the authors to give readers additional information about their work.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Quick Reference
The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Who Should Be Assessed for Migraine?
All results at
JAMAevidence.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Need assistance?
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.


text:
Office of Management and Budget
Ms. Moone is the Deputy Chief Human Capital Officer and Human Capital Director for the Office of Management and Budget (OMB), Executive Office of the President (EOP). She is assigned to the Management and Operations Division and provides leadership in agency human capital planning and policy. In this role, she supports and advises the Chief Human Capital Officer in the management of program and policy development for OMB's workforce and on applicable laws and regulations.
Prior to joining the EOP, Jamesa served as a Senior Analyst for the U.S. Department of Education. In this role, she was responsible for the finance and administration of federal grants for both the Office of Elementary and Secondary and Education and Office Postsecondary Education. She was also a Management and Program Analyst for the National Institutes of Health, National Institute of General Medical Sciences.
In addition to her federal experience, Jamesa also has extensive leadership and human resources experience in the private sector and higher education. She served as a Senior Consultant for Datatel, Inc. where she managed product demonstration and training; as the Director for Staff Development at American University overseeing human resources, recruitment and training for the Office of Residential Life and Housing; the Assistant Director of Human Resources for the University of Maryland's (College Park) Office of Residence Life; Director of Student Affairs and Residential Life at Mount Vernon College of George Washington University; and as an Affirmative Action Officer for Montgomery College (Rockville, Maryland).
Jamesa has also served as a faculty member at the University of Maryland and Mount Vernon College. She earned a Bachelor of Arts degree in English from Hampton University and a Master's degree in Education Policy and Leadership from Miami University (Ohio). She has received numerous awards during her career, including a Professional Achievement Award for superior leadership and performance, a Diversity Award for exceptional commitment and outstanding service in the advancement of Equal Employment Opportunity and Length of Service Award – all from the Office of Management and Budget.


text:
From the Lenoir County Sheriff's Office:
December 19, 2012
The Lenoir County Sheriff's Office responded to a reported motor vehicle breaking and entering on the 2500 block of Pinewood Home Drive, in Pink Hill just before midnight on Saturday December 15.
It was reported to the Lenoir County 911 center that the homeowner's 16 year old grandson had witnessed someone running away wearing a light colored shirt near their 2002 Ford Ranger Pickup that was parked in their driveway.
Shortly thereafter, Sheriff's Office Patrol units responded to a reported burglary at a residence on the 2600 Block of Pinewood Home Drive, Pink Hill. The homeowner came home and observed that someone had broken into her home some time that Saturday evening.
Through further investigation it was discovered that during the burglary, the home was heavily vandalized and her children's Christmas presents were opened and their contents stolen. A search of the area led to locating some of the homeowners personal items left abandoned in a pillow case on her property.
Sheriff's Office Patrol along with Det. J. Whitley conducted a search of the area Sunday afternoon. Law enforcement located two men that were temporarily staying in the neighborhood. It was reported the two men were renting living space inside a horse barn at 4345 Rosewood Drive, Pink Hill. Further investigation identified some of the stolen property located in the horse barn with the two men.
Donald Wesley Shepard Jr, 25, of Greensboro, along with Michael Edwards Clark, 23, of Jamesville, were charged with the following;
One count each of second degree burglary (F), larceny after B&E (F), possession of stolen goods (F),
iInjure to building/fence/wall (F),breaking out of a dwelling and breaking and entering a motor vehicle.
Both men are currently in the Lenoir County Jail under a $ 95,000 secured bond.
Information concerning a crime can be reported directly to the Lenoir County Sheriff's Office at 252-559-6100, through the Lenoir County Crimestoppers at 252-523-4444 or email the information to www.co.lenoir.nc.us go to the link: E-Tips to leave your information anonymously.


text:
Prices shown in currencies other than USA Dollars are estimates based on current exchange rates. We will charge your credit card in USA Dollars on the day your order is shipped, and the conversion to your local currency will be done at the prevailing rate by your credit card issuer.
Shipments outside the USA are declared as "bike parts" for customs purposes and will include the actual amount paid for merchandise and shipping. Jenson USA will not mark your parcel as a "gift", declare a value lower than the actual price paid, or otherwise prepare false customs information.
Tell a friend! We'll send your friends the page and your message.
Note: You and your friend's email addresses are only used once as a referral. We will not collect or store the email addresses.
Reviewed by 2 customers
Sort by
Best Uses
Comments about Yakima Viper Bike Carrier:
I was excited to finally have a roof rack and bike tray only to be let down. If you have disc brakes and they are no bigger than 160mm then you will love this bike tray. All my bikes are 180mm+ and the caliper's hit the tray before the fork can properly sit on the skewer. It would have been nice to know this before I wasted my $ on over sized shipping. Now I have to return the tray and spend more $ to ship it back over sized again. I even checked the Yakima site to make sure I would not have any surprises like this but even there it doesn't say anything about bikes not fitting with calipers larger than 160mm.
Best Uses
Comments about Yakima Viper Bike Carrier:
Looks great, definately worth the extra money over the Copperhead series. Fits my mtn bike with fat 2.3 inch tires and well as my road bike's skinny 23mm tires.
Jenson USA ships worldwide, including APO/FPO addresses. For a quote, simply add the items you are interested in to your shopping cart and look for the "Shipping Options" box. You don't have to login or create an account to see shipping charges.
Some manufacturers restrict where we can ship their products. If this item has shipping restrictions, they are listed below. If you'd like to buy an item that we cannot ship to your preferred address, we can accept your foreign credit card and ship to a USA address for you.
Get free shipping with your $50 purchase today when you choose Standard Shipping at checkout. Please note this offer is only available to physical shipping addresses in the 48 continental United States (no PO Boxes), and oversize charges still apply on some heavy/large itemsDue to manufacturer restrictions, this product cannot be shipped to the following locations:
Get free Standard Shipping with your $50 purchase today! Just choose Standard Shipping during checkout.
Please note this offer is only available to physical shipping addresses in the 48 continental United States (no PO Boxes), and oversize charges still apply on some heavy/large items.


text:
Religion is believing in something, and everybody does that, even if its in nothing.
I've done my share. Born a Catholic, considered priesthood, decided on nihilism, turned to "Born-Againism", became A-religious, turned to JWism (still am at this point but stagnant, studying "New-Agism" and recently ran across this site.
Here they say that "ism's" should become "wasm's".
You see at the age of 58, you would think that I'd have my life choices to rest on, but I don't!
Life is a very confusing event, for a person searching for the truth.
Truth is, truth is very relative. Relative to what you can accept.
I have been able to accept a lot, but it always leads to other questions, and its getting very frustrating.
I probably could present a relatevely good argument against all of these beliefs, but defending "my" belief against "theirs" just seems so futile for the remainding years of my life.
I have been leaning towards "Oneness".
Seems to sum it all up.
We are all individual parts of "the Whole".
The Whole wants to live, but needs the support of the parts. Sort of like the human body.
Like the body, some parts are infirmed. Does that mean I cut them off? Not until they debilitate to a point of no return, and then that is the surgeons job.
Until then, I will do my best to produce the medicine that the body needs to heal.
I think that element is love, and that is what I determine to administer to the rest of "my" body and hope "I'll" come out Whole.
On second thought, maybe I do have my life choices to rest on!
"Rest in Peace" is a nice saying when your still alive.


text:
You can indicate the ring size, special gift wrapping or any other request to the designer at checkout.
Mademoiselle Felee's Aurore François is a Parisian designer whose jewelry collections are tributes to the
City of Lights. The Eiffel Tower naturally sits at the heart of her work, and
Aurore finds creative ways to integrate elements of the famous design into her
jewels, preserving a little bit of Paris to send around the world.


text:
+ - Developer required for pothole identification-> 1
Submitted by mikejuk
mikejuk writes: The city of Boston has already devised a novel Android app for pothole identification and has now posted a bounty of $25,000 for an algorithm to improve it. Using the accelerometer to detect bumps as people drive round the city is clever. When multiple phones report the same jolt, the app identifies a pothole that needs to be repaired and this is clever. But... they can't tell the difference between things like railway crossings and sewer gratings from potholes and so are offering $22,500 to any programmer who can work out an algorithm that can tell the difference.
Don't they have city maps in Boston?
Link to Original Source
Don't they have city maps in Boston?
Link to Original Source


text:
Parquet Courts Biography & News
Parquet Courts Details
|Official site
About Parquet Courts
About Parquet Court
They offer up a special breed of "American punk," which is something quite unique for these former Texans turned Brooklynites. But make no mistake – the popularity of Parquet Courts has been building steadily since 2011, and if you heard them you'd know why.
Featuring Andrew Savage (vocals, guitar), Austin Brown (vocals, guitar), Sean Yeaton (bass) and Max Savage (drums), Parquet Courts has been producing its own brand of indie rock married with jagged punk since cassette distribution of its first album in 2011. That project, "American Specialties," was the catalyst for a more widely distributed full-length album, "Light Up Gold," issued in the summer of 2012.
Parquet Courts quickly booked its first full U.S. tour by the end of the year, and when "Light Up Gold" was reissued it quickly took on a life of its own in the indie rock world. It pushed the band to constant press, constant touring and straight back into the studio for its next record, a five-song EP, "Tally All the Things That You Broke," in 2013.
The band's full-length second album, "Sunbathing Animal, " was released in June of 2014, and was again followed up with a collection of recordings almost immediately, including the album-length "Content Nausea" as Parkay Quarts in November.
Parquet Courts Ticket PricesFind Tickets
Past 12 Months
$294Average Price
$1,945High price
$9Low price
Cost for Upcoming Parquet Courts Shows
$127Average Price
$194 - 428Listing RangeIn Secondary Market
Past Tour Dates for Parquet Courts
Parquet Courts Tour Dates 2015
date city state venue 04/17/2015 Indio CA Empire Polo Field 04/17/2015 Indio CA Empire Polo Field 03/09/2015 Auckland Auk Kings Arms 02/10/2015 Brooklyn NY Palisades 02/09/2015 Brooklyn NY Palisades 02/08/2015 Philadelphia PA First Unitarian Church 02/07/2015 Washington DC Black Cat 02/06/2015 Asheville NC The Mothlight 02/05/2015 Nashville TN Exit In 02/04/2015 Birmingham AL The Bottletree Cafe 01/29/2015 Atlanta GA The Earl 01/28/2015 Athens GA 40 Watt Club 01/26/2015 Raleigh NC Kings Barcade 01/25/2015 Charlottesville VA The Southern Cafe and Music Hall 01/24/2015 Baltimore MD Ottobar 01/07/2015 Washington DC Black Cat
Parquet Courts Tour Dates 2014
date city state venue 12/11/2014 New York NY Webster Hall 11/30/2014 Zurich ZH Rote Fabrik 11/27/2014 London The Laundry 11/26/2014 Leeds W York The Wardrobe 11/25/2014 London Lnd Electrowerkz 11/20/2014 Brussels Brussels-capital Reg Botanique 11/13/2014 Tourcoing B4 Le Grand Mix 11/08/2014 Philadelphia PA PhilaMOCA 11/06/2014 Washington DC DC9 Nightclub 10/22/2014 Cambridge MA The Sinclair 08/05/2014 Seattle WA Vera Project 08/02/2014 Chicago IL Grant Park 08/01/2014 Happy Valley OR Pendarvis Farm 08/01/2014 Chicago IL Grant Park 08/01/2014 Chicago IL Grant Park 07/18/2014 Dublin D Marlay Park 07/17/2014 Beccles Sfk Henham Park 07/16/2014 Berlin BE Cassiopeia 07/10/2014 Bilbao Basque Country Kobetamendi Park 07/09/2014 La Rochelle B7 La Sirene 07/08/2014 Paris ?? Le Divan du Monde 07/03/2014 Werchter Vbr Werchter Park 06/26/2014 Oxford Oxf O2 Academy Oxford 06/25/2014 Pilton Som Worthy Farm 06/25/2014 London London University of London 06/23/2014 Birmingham War The Institute 06/22/2014 Liverpool Lancashire The Kazimier Club 06/21/2014 Glasgow Glg SWG3 06/11/2014 Brooklyn NY Sugarhill Supper Club 06/10/2014 Cambridge MA TT The Bears 06/08/2014 Toronto ON Horseshoe Tavern 06/07/2014 Detroit MI PJ's Lager House 06/06/2014 Columbus OH Double Happiness 06/05/2014 Nashville TN Third Man Records 06/03/2014 Dallas TX Club Dada 06/02/2014 Houston TX Fitzgerald's 05/29/2014 Austin TX Red 7 05/28/2014 West Hollywood CA The Roxy Theatre 05/28/2014 Austin TX Red 7 05/27/2014 San Francisco CA The Independent 05/24/2014 Vancouver BC Biltmore Cabaret 05/23/2014 George WA Gorge Amphitheatre 05/23/2014 Portland OR Doug Fir Lounge 05/22/2014 Calgary AB Commonwealth Bar & Stage 03/13/2014 Austin TX Bar 96 03/02/2014 Cleveland OH Beachland Ballroom 02/16/2014 London London Electric Ballroom 02/15/2014 Manchester Gtm Manchester Academy 2 02/14/2014 Brighton Sxe Concorde 2 01/20/2014 Phoenix AZ Crescent Ballroom 01/19/2014 Pioneertown CA Pappy & Harriet's 01/18/2014 La Jolla CA Che Cafe 01/17/2014 Los Angeles CA Fonda Theatre 01/16/2014 San Francisco CA Great American Music Hall 01/14/2014 Brooklyn NY The Acheron
Parquet Courts Tour Dates 2013
date city state venue 10/31/2013 Glasgow Glg Mono 10/30/2013 Leeds Yorkshire Brudenell Social Club 10/29/2013 Manchester Man Manchester Gorilla 10/28/2013 London Lnd Village Underground 10/27/2013 Brussels Bru Ancienne Belgique 10/26/2013 Paris Ville De Paris La Maroquinerie 10/23/2013 Munich BY Atomic Cafe 10/19/2013 Hamburg HH Molotow 10/17/2013 Nijmegen GE Doornroosje 10/15/2013 Amsterdam ?? Melkweg 10/02/2013 Brooklyn NY Music Hall of Williamsburg 09/20/2013 New York NY Bowery Ballroom 09/05/2013 Newport Iow Robin Hill Country Park 08/30/2013 Salisbury Dor Larmer Tree Gardens 08/23/2013 Leeds Yorkshire Bramham Park 08/06/2013 Oslo 03 Middelalderparken 07/21/2013 Chicago IL Bottom Lounge 07/18/2013 Chicago IL Lincoln Hall 07/17/2013 Toronto ON Horseshoe Tavern 07/15/2013 Burlington VT Signal Kitchen 07/13/2013 Cambridge MA TT The Bears 07/07/2013 Rotterdam Zuiderpark 06/26/2013 Buffalo NY Tralf Music Hall 06/25/2013 Detroit MI Magic Stick 06/23/2013 Bloomington IN The Bishop 06/22/2013 Madison WI High Noon Saloon 06/21/2013 Minneapolis MN Triple Rock Social Club 06/20/2013 Omaha NE Sweatshop Gallery 06/19/2013 Denver CO Larimer Lounge 06/18/2013 Salt Lake City UT Urban Lounge 06/17/2013 Boise ID Neurolux Lounge 06/15/2013 Victoria BC Copper Owl 06/14/2013 Vancouver BC Electric Owl 06/13/2013 Seattle WA Neumos 06/10/2013 Davis CA Davis Bike Collective 06/09/2013 Oakland CA 1-2-3-4 Go! Records 06/07/2013 San Francisco CA Rickshaw Stop 06/05/2013 Los Angeles CA The Echo 06/04/2013 La Jolla CA Che Cafe 06/03/2013 Phoenix AZ Rhythm Room 06/02/2013 Marfa TX El Cosmico 05/21/2013 Amsterdam North Holland Bitterzoet 05/20/2013 London London Rough Trade East 05/19/2013 London Lnd 100 Club 05/16/2013 Brighton Bnh Brighton Dome 05/06/2013 New York NY Webster Hall 05/04/2013 Philadelphia PA PhilaMOCA 03/22/2013 Brighton East Sussex Audio 03/21/2013 London Lnd Sebright Arms 03/20/2013 London Hck The Shacklewell Arms 03/02/2013 Providence RI AS220 02/28/2013 Purchase NY Performing Arts Center Purchase College 02/23/2013 Greensboro NC The Blind Tiger 02/22/2013 Washington DC Black Cat 02/16/2013 Philadelphia PA Voyeur Nightclub 02/15/2013 New London CT Connecticut College 02/02/2013 New York NY 285 Kent Avenue 02/02/2013 Brooklyn NY 285 Kent 01/20/2013 Olympia WA The Northern 01/19/2013 Seattle WA Cairo 01/18/2013 Portland OR Bunk Bar 01/16/2013 San Francisco CA Hemlock Tavern 01/15/2013 Los Angeles CA The Echo 01/10/2013 Philadelphia PA Kung Fu Necktie 01/07/2013 Columbus OH Cafe Bourbon Street 01/03/2013 Beaumont TX Victoria House 01/02/2013 Austin TX Beerland
Parquet Courts Tour Dates 2012
date city state venue 12/31/2012 Denton TX Rubber Gloves 12/30/2012 Oklahoma City OK Bad Granny's Bazaar 12/28/2012 Omaha NE The Middle House 12/27/2012 Chicago IL Empty Bottle 12/26/2012 Detroit MI Jumbo's Bar 12/21/2012 Brooklyn NY Warsaw


text:
Ahhh....Originally posted by spongey
Sure thing. If someone can get me some pictures to post on the website, everyone that went will get a point (except for the person who takes pictures, that's +2!)
It's on now. The Sony will be there.
Hey news-boy!!!Quote by say-what:
I think I will bring my camera this time just to give GA some competition.
Don't you have enough to do and now you want to move in on my territory. Keep your nose out of my business. The picture-taking job is mine!


text:
Stormers head coach Allister Coetzee says Schalk Burger will be fit for the 2013 Super Rugby season.
The veteran flank missed the entire 2012 season after injuring his knee during the Stormers' Super Rugby opener against the Hurricanes.
The 29-year-old is currently busy with his rehab, but will rejoin the team at training on 7 January and is expected to play in the first pre-season match on 2 February.
Meanwhile, Coetzee told Heart 104.9FM's Sportswrap that Elton Jantjies won't be promised any game time while Jaco Taute will play fullback during Super Rugby next year.
The Springbok flyhalf is likely to start for the Stormers at the start of Super Rugby, because of 2012 incumbent Peter Grant's commitments with Japanese club the Kobe Steelers until late February and Currie Cup-winning flyhalf Demetri Catrakilis's departure to the Southern Kings.
This will please the Lions, who want their players to get a good amount of game time during their respective loans, especially ahead of the Super Rugby promotion-relegation play-offs in July and August.
However, Coetzee stressed that no set amount of playing time has been agreed. It's also believed that Grant will return to the Stormers starting line-up once he's settled in Cape Town.
'No, [Jantjies' game time] has nothing to do with anyone,' said Coetzee. 'We've experienced in Super Rugby that you need to have enough depth in your team's spine, that includes your hooker, No 8, your 9 and 10 and your 15. Also tighthead prop. We'll have that at flyhalf with Peter and Elton there, and with youngsters like Kurt Coleman and Gary van Aswegen.'
When speaking about Taute, Coetzee confirmed that the utility back will compete for the No 15 jersey with Joe Pietersen.
Taute has played mostly at centre in 2012. He featured prominently in the midfield for the Lions, while he's played three Tests at outside centre for the Springboks.
'Jaco's best position – and he'll tell you that – is 15,' said Coetzee. 'From his provincial U21 and SA U20 days, he's been a talented fullback. He joins the line well and has great running skills. He's a big strong lad in the last line of defence. And he's got a good boot on him – he kicks for poles and puts in long-range kicks. He'll give the team a bit of punch from the back.'
Good news for the Stormers is that Taute will consider signing a permanent deal with the Stormers if all goes well during his loan. The player confirmed his interest of extending his stay with this site in October.


text:
Benefit Administration
We Welcome All New Employees and Faculty to Texas A&M University-Texarkana!!!
New Employees and Benefit Information
Make your Benefit elections in the iBenefits section! Click on the Single Sign On link below.
Employees can find more information on their specific benefits on HRConnect through Single Sign On.
TRS/ORP Overview Booklet
2013-2014 Benefits Guide
2014-2015 Premium Rates
2014-2015 Benefits Guide
Benefit Forms
New Employee Benefit Enrollment Form
Dependent Enrollment/Change Form
Benefit Change Form
Express Scripts Claim Form
Delta Dental Claim Form
Plan Description Booklets
A&M Health Care Plans
Dental Plan
Vision Plan
Life Insurance
Accidental Death and Dismemberment
Long Term Disability
Flexible Spending Accounts
Retirement Information
Working Retirees Information
TRS Retirement SB 1668 made some interesting changes to the way TRS retirees can work. Please see the links below for more information:
SB 1668 and Frequently Asked Questions
Retirement Brochures
A Guide To Your Retirement Programs
Retirement Planning
A Look Ahead to Retiring From Texas A&M University
Frequently Asked Questions
Retirement Forms
ORP/TDA Forms
Medicare Coordination Form
Retiree Benefit Enrollment Form
Phone Numbers for Reference
Blue Cross Blue Shield Heath Coverage - A&M Care 1-866-295-1212 http://www.bcbstx.com
Delta Dental - A&M Dental 1-800-336-8264 http://www.deltadentalins.com/tamus/
Cigna Insurance Long-Term Disability 1-800-36-CIGNA http://www.cigna.com/
Minnesota Life Insurance 1-877-282-1752 https://web1.lifebenefits.com/lb/home.htm
Express Scripts - A&M Care Prescription Drug Program 1-866-544-6970 https://www.express-scripts.com/
PayFlex - Flexible Spending Accounts 1-800-284-4885 http://www.healthhub.com/
EyeMed Vision 1-866-939-3633 http://www.eyemedvisioncare.com/


text:
Create More Space with an Outdoor Shed
If you have a yard and a set of appliances or tools used specifically for the yard, it's a good idea to consider building yourself an outdoor shed to house these items. Lawnmowers, hoses, buckets, shovels, etc. can all take up a lot of valuable space in a small garage. You'll find your space more useable if it is assigned based on function.
The main thing to remember once you've organized your garage is maintenance, maintenance, maintenance! Get used to putting tools and equipment back where they came from and do a routine clean-up after every major home improvement project that utilizes multiple items from the garage. Once you realize the potential cleanliness and order your garage can have, don't ever get caught in the muck of disorganization again. Your garage will look better; you'll feel better; and you will have a much easier time utilizing the items and space in your garage. Good luck!
Source: http://www.networx.com/article/whip-your-garage-into-shape


text:
PORTLAND -- The rush at Portland area gun stores started after the shooting at Clackamas Town Center, but erupted hours after the massacre in Connecticut.
We had the busiest day we've ever had in over 20 years the day of the shooting, and it looks like Saturday will be even bigger, said Karl Durkheimer who owns Northwest Armory in Milwaukie.
Local gun stores are so busy, state background checks that usually take 15 minutes, now have customers waiting four hours.
Even so, gun buyers like Brett Eyman are more than willing to wait. He's buying a semi-automatic rifle because he believes his right to buy one may soon be going away.
I believe its coming to an end in the next year, said Eyman.
The guns in our community have nothing to do with hunting and they have to do with killing people and we have to get real about that, said State Senator Ginny Burdick.
Burdick is a long-time gun control advocate and believes more needs to be done to keep guns out of the hands of children and criminals. She's also introduced a bill limiting gun magazines to ten bullets.
If you limit the size of magazines, you limit the number of shots someone can get off rapidly before changing clips, said Burdick.
President Clinton passed a similar federal law limiting bullets in 1994, but it expired 10 years later.
The shootings in Clackamas and Connecticut have people on both sides of the gun control debate fired up.
Obviously this rush has to do with what happened in the mall and the school. People have fear that the weapons they want will soon be more difficult to acquire, said gun owner Ray Hettwer.
I think you're going to see people, including gun owners, get engaged to end this madness, said Sen. Burdick.
In the meantime, it appears guns and ammo of all kinds will be flying off the shelves.


text:
News Archive
Awake mental replay of past experiences is essential for making informed choices, suggests a study in rats. Without it, the animals' memory-based decision-making faltered, say scientists funded by the National Institutes of Health.
Awake mental replay of past experiences is essential for making informed choices, suggests a study in rats. Without it, the animals' memory-based decision-making faltered, say scientists funded by the National Institutes of Health.
Monday, May 7, 2012 - 15:38
UC Davis Health System researchers are a step closer to launching human clinical trials involving the use of an innovative stem cell therapy to fight the virus that causes AIDS.
Friday, May 4, 2012 - 15:08
Researchers studying multiple sclerosis (MS) have long been looking for the specific molecules in the body that cause lesions in myelin, the fatty, insulating cells that sheathe the nerves. Nearly a decade ago, a group at Mayo Clinic found a new enzyme, called Kallikrein 6, that is present in abundance in MS lesions and blood samples and is associated with inflammation and demyelination in other neurodegenerative diseases. In a study published in Brain Pathology, the same group found that an antibody that neutralizes Kallikrein 6 is capable of staving off MS in mice.
Thursday, May 3, 2012 - 15:18
Collaborative research by groups headed by scientists Joan J. Guinovart and Marco Milán at the Institute for Research in Biomedicine (IRB Barcelona) has revealed conclusive evidence about the harmful effects of the accumulation of glucose chains (glycogen) in fly and mouse neurons.
Wednesday, May 2, 2012 - 16:01
Anxious mice get more serious cancer than their calmer counterparts, according to a new study that could have implications for human cancer treatments.
Tuesday, May 1, 2012 - 13:48
Tuesday, April 24, 2012 - 12:34
Mice got new vision and revived heart muscles and monkeys were able to flex muscles in paralyzed hands in research reported today that has extended the boundaries of regenerative medicine beyond the test tube.
Friday, April 20, 2012 - 15:52
A Northwestern Medicine scientist has developed the first blood test to diagnose major depression in teens, a breakthrough approach that allows an objective diagnosis by measuring a specific set of genetic markers found in a patient's blood.
Wednesday, April 18, 2012 - 16:29
Tuesday, April 17, 2012 - 16:08
Expanding on previous research providing proof-of-principle that human stem cells can be genetically engineered into HIV-fighting cells, a team of UCLA researchers have now demonstrated that these cells can actually attack HIV-infected cells in a living organism.
Friday, April 13, 2012 - 15:31
A potential new treatment for type 2 diabetes targets the hormone glucagon instead of insulin, according to a new study in mice.
Thursday, April 12, 2012 - 17:10
Alzheimer's disease (AD) is now the sixth leading cause of death among Americans. There is currently no treatment that alters the course of this disease. However, an increasing amount of evidence suggests that changes in the way the body handles iron and other metals like copper and zinc may start years before the onset of AD symptoms. A study using rabbits shows that reducing iron levels in blood plasma may protect the brain from changes related to AD.
Wednesday, April 11, 2012 - 16:14
Tuesday, April 10, 2012 - 11:33
A GROUP of mice have returned to Earth after the longest mission any animal has endured in space. The mice were floating around for 91 days to test a way to prevent the breakdown of bone.
Monday, April 9, 2012 - 16:16
A drug developed by Baker IDI scientists could help treat Duchenne Muscular Dystrophy (DMD), a severe and progressive muscle wasting disease that affects young boys, according to a study published today in Nature.
Friday, April 6, 2012 - 14:10
Babies who are born small have a tendency to put on weight during childhood and adolescence if allowed free access to calories. However, an animal model study at UCLA found when small babies were placed on a diet of moderately regulated calories during infancy, the propensity of becoming obese decreased.
Thursday, April 5, 2012 - 16:24
Research conducted by the University of Minnesota's College of Veterinary Medicine could help owners of severely epileptic dogs predict, control and more effectively treat their pets' seizures.
Wednesday, April 4, 2012 - 16:07
New figures from the Centers for Disease Control (CDC) show autism is on the rise, affecting one in 88 children born. It's a growing health problem. Scientists in San Antonio are using an animal model to help find answers to this mysterious condition.
Tuesday, April 3, 2012 - 15:03
Those with type II diabetes are at two to three times the risk of developing primary liver cancer. But new research from the University of Maryland shows that a common drug many patients already take may prevent the cancer. Studies on animals show that the diabetes drug metformin may help prevent liver tumors from growing.
Monday, April 2, 2012 - 16:17
A new animal model of nerve injury has brought to light a critical role of an enzyme called Nmnat in nerve fiber maintenance and neuroprotection. Understanding biological pathways involved in maintaining healthy nerves and clearing away damaged ones may offer scientists targets for drugs to mitigate neurodegenerative diseases such as Huntington's and Parkinson's, as well as aid in situations of acute nerve damage, such as spinal cord injury.
Friday, March 30, 2012 - 13:54